These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32690996)

  • 1. COVID-19 infection: mitohormetic concept of immune response.
    Gebicki J; Wieczorkowska M
    Cell Death Discov; 2020; 6():60. PubMed ID: 32690996
    [No Abstract]   [Full Text] [Related]  

  • 2. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
    Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
    Front Immunol; 2020; 11():1942. PubMed ID: 32983123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.
    Perlin DS; Neil GA; Anderson C; Zafir-Lavie I; Raines S; Ware CF; Wilkins HJ
    J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34871182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.
    Khudadah K; Ramadan A; Othman A; Refaey N; Elrosasy A; Rezkallah A; Heseba T; Moawad MHED; Mektebi A; Elejla SA; Abouzid M; Abdelazeem B
    Biosci Rep; 2023 Aug; 43(8):. PubMed ID: 37497603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Approaches for Intravascular Microthrombi-induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Infection.
    Gopika KM; Sivajith S; Sugunan A; Sudheesh MS
    Curr Pharm Biotechnol; 2023; 24(8):970-987. PubMed ID: 35838218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.
    Sahebnasagh A; Mojtahedzadeh M; Najmeddin F; Najafi A; Safdari M; Rezai Ghaleno H; Habtemariam S; Berindan-Neagoe I; Nabavi SM
    Arch Med Res; 2020 Oct; 51(7):631-635. PubMed ID: 32863034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review.
    Montenegro F; Unigarro L; Paredes G; Moya T; Romero A; Torres L; López JC; González FEJ; Del Pozo G; López-Cortés A; Diaz AM; Vasconez E; Cevallos-Robalino D; Lister A; Ortiz-Prado E
    Expert Rev Respir Med; 2021 Feb; 15(2):183-195. PubMed ID: 32902367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute respiratory distress syndrome secondary to COVID-19 mRNA vaccine administration in a pregnant woman: A case report.
    Abraham B; Mohammed Saeed H; Azeez Pasha SA
    Qatar Med J; 2022; 2022(3):40. PubMed ID: 35974885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 in Lung Transplant Recipients: 2 Cases With Acute Respiratory Distress Syndrome Successfully Treated With High-Dose Corticosteroids.
    Brugiere O; Neuville M; Le Balch P; Le Tulzo Y; Brun AL; Hamid A; Beaumont L; Roux A; Jouneau S; Parquin F
    Exp Clin Transplant; 2021 Jul; 19(7):744-748. PubMed ID: 34085913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome.
    Venet F; Cour M; Rimmelé T; Viel S; Yonis H; Coudereau R; Amaz C; Abraham P; Monard C; Casalegno JS; Brengel-Pesce K; Lukaszewicz AC; Argaud L; Monneret G;
    Crit Care; 2021 Apr; 25(1):140. PubMed ID: 33845874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and lung mechanics characteristics between COVID-19 and non-COVID-19-associated acute respiratory distress syndrome: a propensity score analysis of two major randomized trials.
    Tomazini BM; Costa ELV; Besen BAMP; Zampieri FG; Carvalho CRR; Caser EB; Souza-Dantas VC; Boschi E; Fumis RRL; Alencar Filho MS; Maia IS; Oliveira Filho W; Veiga VC; Avezum A; Lopes RD; Machado FR; Berwanger O; Rosa RG; Cavalcanti AB; Azevedo LCP
    Rev Bras Ter Intensiva; 2022; 34(3):335-341. PubMed ID: 36351065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunological response among COVID-19 patients with acute respiratory distress syndrome.
    Almutairi AS; Abunurah H; Hadi Alanazi A; Alenazi F; Nagy H; Saad Almutairi N; Wells M; Alawam A; Alqahtani MM
    J Infect Public Health; 2021 Jul; 14(7):954-959. PubMed ID: 34130119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.
    Rein L; Calero K; Shah R; Ojielo C; Hudock KM; Lodhi S; Sadaka F; Bellam S; Palma C; Hager DN; Daniel J; Schaub R; O'Hayer K; Theodoropoulos NM
    Crit Care Med; 2022 Dec; 50(12):1701-1713. PubMed ID: 36226977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophils and secondary infections in COVID-19 induced acute respiratory distress syndrome.
    Holliday ZM; Alnijoumi MM; Reed MA; Earhart AP; Schrum AG; Allen LH; Krvavac A
    New Microbes New Infect; 2021 Nov; 44():100944. PubMed ID: 34567574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Documenting the immune response in patients with COVID-19-induced acute respiratory distress syndrome.
    Lu J; Zeng X; Lu W; Feng J; Yang Y; Wei Y; Chen Y; Zhang J; Pinhu L
    Front Cell Dev Biol; 2023; 11():1207960. PubMed ID: 37363730
    [No Abstract]   [Full Text] [Related]  

  • 17. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome.
    Lin F; Ichim TE; Pingle S; Jones LD; Kesari S; Ashili S
    World J Stem Cells; 2020 Oct; 12(10):1067-1079. PubMed ID: 33178392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher Risk of Acute Respiratory Distress Syndrome and Risk Factors among Patients with COVID-19: A Systematic Review, Meta-Analysis and Meta-Regression.
    Tsai YT; Ku HC; Maithreepala SD; Tsai YJ; Chen LF; Ko NY; Konara Mudiyanselage SP
    Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prone Position in COVID-19 and -COVID-19 Acute Respiratory Distress Syndrome: An International Multicenter Observational Comparative Study.
    Camporota L; Sanderson B; Chiumello D; Terzi N; Argaud L; Rimmelé T; Metuor R; Verstraete A; Cour M; Bohé J; Piriou V; Beuret P; Guérin C
    Crit Care Med; 2022 Apr; 50(4):633-643. PubMed ID: 34582426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: Inflammatory Profile.
    Wang Y; Perlman S
    Annu Rev Med; 2022 Jan; 73():65-80. PubMed ID: 34437814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.